Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Metastatic HR+/HER2- Breast Cancer Market Today And What Is Its Future Size?

The market size of metastatic hr+/her2- breast cancer has seen robust growth in the recent past. The market, which is projected to be $9.91 billion in 2024, will witness a rise to $10.89 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.0%. The surge during the historical period can be credited to heightened awareness around early detection, an uptick in diagnosis rates, fruitful clinical trials, investments in pharmaceutical and expanded use of combination therapies.

The market for metastatic hr+/her2- breast cancer is projected to experience substantial augmentation within the next few years, eventually reaching $15.79 billion by 2029, with a CAGR of 9.7%. Factors contributing to this anticipated growth over the forecast period include an increased acceptance of new therapeutic options, expanding use of immunotherapy, breaking into upcoming markets, the existence of patient support and advocacy programs, and an emphasis on improving patients’ quality of life. Key trends expected in the forecast period encompass next-generation sequencing (NGS), enhancements in liquid biopsy, the unearthing of biomarkers, advancements in cell and gene therapy, and the proliferation of monoclonal antibodies (mAbs).

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp

Which Key Factors Are Fueling Growth In The Metastatic HR+/HER2- Breast Cancer Market?

The growth of the metastatic HR+/HER2- breast cancer market is anticipated to be driven by the rising prevalence of hormone replacement therapy (HRT). This therapeutic method, which is often utilized for hormone deficiencies or during menopause when there is a decrease in hormone levels, is progressively being employed due to its effectiveness in enhancing therapeutic outcomes. Not only does it present fewer side effects compared to traditional therapies, but it also benefits from advances in precision medicine. HRT can aid metastatic HR+/HER2- breast cancer by mitigating the estrogen deficiency symptoms linked with menopause, like hot flashes and vaginal dryness. It does so without affecting the potency of endocrine therapies since its primary focus is on rectifying hormone imbalances instead of targeting the cancerous cells. This results in an enhanced quality of life for patients undergoing cancer treatment. NHS England, a Government agency in the UK, reported in October 2023, that during 2022-23, there were 11 million HRT items prescribed in England. This represented a 47% increase from the previous year. Hence, the growing utilization of HRT fuels the metastatic HR+/HER2- breast cancer market.

How Is The Metastatic HR+/HER2- Breast Cancer Market Segmented Across Key Categories?

The metastatic hr+/her2- breast cancermarket covered in this report is segmented –

1) By Drugs: Paclitaxel; Tamoxifen; Vinblastine; Raloxifene; Docetaxel; Other Drugs

2) By Treatment: Radiation Therapy; Vitamin Therapy; Macrobiotic Diets; Homeopathy; Herbal Medication

3) By End-User: Hospitals; Clinics; Other End-User

Subsegments:

1) By Paclitaxel: Generic Paclitaxel; Taxol

2) By Tamoxifen: Generic Tamoxifen; Nolvadex

3) By Vinblastine: Generic Vinblastine; Velban

4) By Raloxifene: Generic Raloxifene; Evista

5) By Docetaxel: Generic Docetaxel; Taxotere

6) By Other Drugs: Letrozole; Anastrozole; Exemestane; Palbociclib; Ribociclib; Abemaciclib

What Current And Upcoming Trends Are Shaping The Metastatic HR+/HER2- Breast Cancer Market?

Key players in the metastatic HR+/HER2- breast cancer market are advancing combination therapies to extend treatment indications and improve therapeutic outcomes. Combination therapy uses multiple treatments simultaneously to increase effectiveness and reduce resistance. In July 2023, US-based Merck & Co., Inc. announced that its Phase 3 KEYNOTE-756 trial evaluating KEYTRUDA (pembrolizumab) with chemotherapy achieved its primary goal. The trial showed a significant increase in the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. It was the first successful Phase 3 study of immunotherapy in this setting, followed by adjuvant treatment with KEYTRUDA and endocrine therapy.

Who Are The Leading Companies Driving The Metastatic HR+/HER2- Breast Cancer Market?

Major companies operating in the metastatic HR+/HER2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Which Region Dominates The Metastatic HR+/HER2- Breast Cancer Market Today?

North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2- breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21220&type=smp

Browse Through More Reports Similar to the Global Metastatic HR+/HER2- Breast Cancer Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Imaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model